Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.
Antonio BellasiPaolo RaggiJordi BoverDavid A BushinskyGlenn M ChertowMarkus KettelerMariano RodriguezSmeeta SinhaCarolina SalcedoRekha GargAlex GoldJoan PerellóPublished in: Clinical kidney journal (2019)
The CaLIPSO trial enrolled patients on haemodialysis with pre-existent cardiovascular calcification to test the hypothesis that SNF472 attenuates its progression in the coronary arteries, aorta and aortic valve.
Keyphrases
- aortic valve
- end stage renal disease
- chronic kidney disease
- study protocol
- double blind
- aortic stenosis
- phase iii
- peritoneal dialysis
- clinical trial
- transcatheter aortic valve replacement
- ejection fraction
- transcatheter aortic valve implantation
- phase ii
- aortic valve replacement
- newly diagnosed
- coronary artery disease
- placebo controlled
- prognostic factors
- heart failure
- aortic dissection